SIREN : 490177649
MEDI FRANCE EUROPE is a French company founded 20 years ago, specialized in the sector Activités des sociétés holding. Based in BORDEAUX (33000), this company of category GE shows in 2024 a revenue of 53 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52 760 € | 66 380 € | 45 130 € | 45 280 € | 44 930 € | 44 970 € | 129 555 € | 201 477 € | 201 516 € | 193 196 € |
| Net income | 370 467 € | -21 103 € | 88 919 € | -103 692 € | 74 189 € | -13 273 € | 311 064 € | 340 612 € | -1 393 267 € | -937 321 € |
| EBITDA | -94 731 € | -84 677 € | -109 200 € | -91 646 € | -118 278 € | -123 881 € | -122 013 € | -33 915 € | -20 398 € | -33 312 € |
| Net margin | 702.2% | -31.8% | 197.0% | -229.0% | 165.1% | -29.5% | 240.1% | 169.1% | -691.4% | -485.2% |
In 2024, MEDI FRANCE EUROPE achieves revenue of 53 k€. Revenue is declining over the period 2015-2024 (CAGR: -13.4%). Significant drop of -21% vs 2023. After deducting consumption (0 €), gross margin stands at 53 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -95 k€, representing -179.6% of revenue. Warning negative scissor effect: despite revenue change (-21%), EBITDA varies by -12%, reducing margin by 52.0 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 370 k€, i.e. 702.2% of revenue. This profit can be retained or distributed to shareholders.
52 760 €
52 760 €
-94 731 €
-117 250 €
370 467 €
-179.6%
The debt ratio (= Financial debt / Equity x 100) stands at 35%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 74%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 22.8 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 719.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
35.098%
73.902%
719.858%
22.764
100.0%
In 2024, the debt ratio of MEDI FRANCE EUROPE (35.10) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of MEDI FRANCE EUROPE (73.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of MEDI FRANCE EUROPE (22.76) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 17733.03. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
17733.031
-149.616
In 2024, the liquidity ratio of MEDI FRANCE EUROPE (17733.03) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of MEDI FRANCE EUROPE (-149.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 34 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 104 days. Excellent situation: suppliers finance 70 days of the operating cycle (retail model). Overall, WCR represents 43824 days of revenue, i.e. 6.4 M€ to permanently finance. Over 2015-2024, WCR increased by +480%, requiring additional financing.
6 422 675 €
34 j
104 j
0 j
43824 j
Based on 54 transactions of similar company sales
in 2024,
the value of MEDI FRANCE EUROPE is estimated at
234 985 €
(range 149 577€ - 1 128 884€).
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDI FRANCE EUROPE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of MEDI FRANCE EUROPE in 2024 is 53 k€.
Yes, MEDI FRANCE EUROPE generated a net profit of 370 k€ in 2024.
The headquarters of MEDI FRANCE EUROPE is located in BORDEAUX (33000), in the department Gironde.
The tax return of MEDI FRANCE EUROPE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDI FRANCE EUROPE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.